Logo

NERV

Minerva Neurosciences, Inc.

NERV

Minerva Neurosciences, Inc. • NASDAQ
$4.20 ▲ 11.11% (+0.42)
Market Cap $29.37 M
52w High $12.46
52w Low $1.15
Dividend Yield 0%
P/E -2.27
Volume 36.63K
Outstanding Shares 6.99M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $2.843M ▼ $-2.744M ▲ 0% $-0.36 ▲ $-2.743M ▲
Q2-2025 $0 $3.374M ▼ $-3.259M ▲ 0% $-0.43 ▲ $-3.257M ▲
Q1-2025 $0 $3.903M ▼ $-3.753M ▲ 0% $-0.5 ▲ $-3.752M ▲
Q4-2024 $0 $4.522M ▲ $-4.272M ▼ 0% $-0.56 ▼ $-4.271M ▼
Q3-2024 $0 $4.367M $22.513M 0% $2.97 $22.519M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $12.287M ▼ $28.092M ▼ $62.672M ▲ $-34.58M ▼
Q2-2025 $15.248M ▼ $30.42M ▼ $62.529M ▲ $-32.109M ▼
Q1-2025 $17.29M ▼ $32.798M ▼ $61.947M ▼ $-29.149M ▼
Q4-2024 $21.362M ▼ $37.144M ▼ $62.837M ▼ $-25.693M ▼
Q3-2024 $26.529M $42.812M $64.483M $-21.671M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.744M ▲ $-2.916M ▼ $0 $-45.166K ▼ $-2.961M ▼ $-2.916M ▼
Q2-2025 $-3.259M ▲ $-2.042M ▲ $0 $0 $-2.042M ▲ $-2.042M ▲
Q4-2024 $-4.272M ▼ $-5.167M ▼ $0 $0 $-5.167M ▼ $-5.167M ▼
Q3-2024 $22.513M ▲ $-4.352M ▼ $0 $0 $-4.352M ▼ $-4.352M ▼
Q2-2024 $-8.233M $-3.937M $0 $0 $-3.937M $-3.937M

Five-Year Company Overview

Income Statement

Income Statement Minerva is still a development-stage biotech with essentially no recurring product revenue. The income statement is dominated by research and administrative costs, which have led to persistent losses over the years. The most recent year looks close to breakeven on paper, but that appears driven by one-off items rather than a shift to a sustainable, profitable business model. Overall, the company remains economically dependent on funding and milestone-type inflows, not on operating earnings.

Balance Sheet

Balance Sheet The balance sheet is very small and quite strained. Cash is limited, total assets are modest, and reported shareholders’ equity has swung from slightly positive to deeply negative, indicating that obligations now far exceed the company’s asset base. Debt has become a meaningful part of the capital structure, which, combined with negative equity, points to a financially fragile position that relies heavily on continued access to external capital.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting ongoing research and corporate spending without offsetting revenue. Capital spending is minimal, so free cash flow is essentially the same as operating cash flow: a steady cash burn. This pattern underscores that Minerva must periodically refill its cash through financings, partnerships, or asset sales to keep funding clinical work.

Competitive Edge

Competitive Edge Commercially, Minerva has no marketed products, so its current competitive position is purely prospective and built around a single key asset, roluperidone. If successful, that drug could be one of the first focused specifically on the negative symptoms of schizophrenia, a meaningful unmet need and a potential niche advantage. However, the FDA setback, the need for another pivotal trial, and active competition from larger, better-funded companies in schizophrenia treatments all make this a precarious and highly concentrated competitive stance.

Innovation and R&D

Innovation and R&D The company’s main strength is its specialized R&D focus in central nervous system disorders, with roluperidone offering a differentiated, non‑dopaminergic approach to negative symptoms of schizophrenia. Prior projects have been discontinued or partnered out, so the pipeline is now quite narrow, but scientifically focused. R&D intensity remains high relative to the company’s size, which is typical for a clinical‑stage biotech but also heightens financial risk if the lead program fails to deliver.

Summary

Minerva Neurosciences sits at a classic high‑risk biotech stage: minimal revenue, ongoing cash burn, a weak balance sheet, and heavy dependence on external financing. The company’s future hinges largely on the outcome of a single confirmatory Phase 3 trial and subsequent regulatory decisions for roluperidone. If the program succeeds, Minerva could gain a foothold in an underserved area of schizophrenia; if not, the lack of diversification and thin financial cushion leave limited fallback options. Anyone tracking the name is effectively tracking the science, the trial execution, and the company’s ability to stay funded long enough to see the results.

NEWS

November 19, 2025 · 8:30 AM UTC

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

Read more

November 5, 2025 · 7:30 AM UTC

Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates

Read more

October 21, 2025 · 8:00 AM UTC

Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved

Read more